Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;12(12):3009.
doi: 10.3390/diagnostics12123009.

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma

Jacopo Moro  1 , Simona Sobrero  1 , Carlotta Francesca Cartia  2 , Simona Ceraolo  3 , Roberta Rapanà  1 , Federico Vaisitti  1 , Stefano Ganio  1 , Federica Mellone  1 , Stefano Rudella  1 , Federico Scopis  1 , Danilo La Paglia  1 , Carola Crystel Cacciatore  1 , Enrico Ruffini  4 , Francesco Leo  1
Affiliations
Review

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma

Jacopo Moro et al. Diagnostics (Basel). .

Abstract

Malignant pleural mesothelioma is a rare cancer characterized by a very poor prognosis. Exposure to asbestos is the leading cause of malignant pleural mesothelioma. The preinvasive lesions, the mesothelial hyperplasia and its possible evolution are the focus of the majority of the studies aiming to identify the treatable phase of the disease. The role of BAP-1 and MTAP in the diagnosis of mesothelioma in situ and in the prognosis of malignant pleural mesothelioma is the main topic of recent studies. The management of preinvasive lesions in mesothelioma is still unclear and many aspects are the subject of debate. The diagnosis, the disease staging and the accurate, comprehensive assessment of patients are three key instants for an appropriate management of patients/the disease.

Keywords: atypical mesothelial hyperplasia; invasive diagnosis of malignant pleural mesothelioma; mesothelioma genetics; mesothelioma histopathology; mesothelioma immunohistochemistry; pleural mesothelial hyperplasia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagnostic diagram for small biopsy specimens with suspect atypical mesothelial hyperplasia.
Figure 2
Figure 2
Interaction between mesothelial cells and talc powder [82].
See this image and copyright information in PMC

References

    1. Nakas A., Martin-Ucar A.E., Edwards J.G., Waller D.A. Localised malignant pleural mesothelioma: A separate clinical entity requiring aggressive local surgery. Eur. J. Cardio-Thoracic Surg. 2008;33:303–306. doi: 10.1016/j.ejcts.2007.09.043. - DOI - PubMed
    1. Ribak J., Lilis R., Suzuki Y., Penner L., Selikoff I.J. Malignant mesothelioma in a cohort of asbestos insulation workers: Clinical presentation, diagnosis, and causes of death. Occup. Environ. Med. 1988;45:182–187. doi: 10.1136/oem.45.3.182. - DOI - PMC - PubMed
    1. SEER Database. [(accessed on 20 June 2022)]; Available online: https://seer.cancer.gov.
    1. Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., Dogan A.U., Pass H.I., Trusa S., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2012;43:1022–1025. doi: 10.1038/ng.912. - DOI - PMC - PubMed
    1. WHO . Classification of Tumors, 5th Edition-Cap-Tumor of Pleura e Pericardium. WHO; Geneva, Switzerland: 2021. pp. 200–201.

LinkOut - more resources